Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PRA International Establishes Legal Entity In New Zealand
New Zealand is a key research location for studies in skin cancer, multiple sclerosis, asthma and several other conditions. PRA International can now monitor New Zealand study sites
New Zealand is a key research location for studies in skin cancer, multiple sclerosis, asthma and several other conditions. PRA International can now monitor New Zealand study sites
China-Biotics said that with this certificate, China-Biotics’ new Qingpu facility is manufacturing all probiotic products under the nation’s strict GMP standard. This certificate is valid through March 28,
Cetrizine hydrochloride is a white, crystalline powder and is water soluble. It is the active component of cetrizine tablets and syrup. It is also an orally active and
MEK is a key protein kinase in the RAS/RAF/MEK/ERK pathway, which signals cancer cell proliferation and survival. MEK has been shown to be frequently activated in cancer, in
NanoBio and the University of Michigan’s, Michigan Nanotechnology Institute for Medicine and Biological Sciences have received funding through a Phase 1 Technology Transfer (STTR) award by the National
Mr Wessels will replace Bob Hartmayer, who is going to retire at the end of 2010. Mr Wessels will to continue to report to Stephan Tanda, member of
Ondansetron injection, USP 2mg/ml is indicated for the prevention of postoperative nausea and vomiting and for the prevention of chemotherapy-induced nausea and vomiting. Ondansetron blocks the actions of
The anti-malarial drug, Artequick, is a four-pill treatment, currently being marketed in 11 countries where the incident rate of malaria is high. As per the terms of the
Bioniche’s research activities are focused mainly on small-scale, bench-top experiments. In order to scale-up the associated processes, a facility is required that houses pilot-scale fermentation equipment and downstream
The results of the first trial, TG-MV-006, confirmed that it had met its primary endpoint with 27.7% of microplasmin treated patients achieving resolution of their VMA compared to